Neural Noise

Motif Neurotech

2 min read

  • Motif Neurotech is developing minimally invasive brain stimulation devices for neurological and psychiatric conditions.1
  • Their approach aims to bridge the gap between fully invasive DBS and non-invasive TMS.1 1

Weekly enrichment (2026-07-20)

  • Motif’s lead product is the DOT (Digitally programmable Over-brain Therapeutic), a millimeter-scale wireless brain stimulator roughly 9 mm across (described as blueberry- or pea-sized) that sits in the skull above the cortex without penetrating the dura or contacting brain tissue.23
  • The device is battery-free, powered by magnetoelectric wireless power-transfer technology invented and patented at Rice University and exclusively licensed by Motif, enabling extreme miniaturization by removing the battery (normally the largest component of implantable stimulators).23
  • On April 27, 2026 the FDA granted an Investigational Device Exemption (IDE) allowing Motif’s first-in-patient clinical trial of DOT for treatment-resistant depression (TRD); this followed a first-in-human demonstration in 2024 that evoked motor responses via motor-cortex stimulation.24
  • The trial (NCT07594483) is a prospective, multi-center, single-arm, open-label early feasibility study with an estimated enrollment of 20 participants, an estimated start of July 2026 and completion around December 2027.5
  • The implant is delivered through a burr hole (~14 mm) over the left dorsolateral prefrontal cortex (DLPFC) in a ~20-minute outpatient procedure; eligibility requires skull thickness between 5.5 mm and 15.5 mm over the target.54
  • The trial’s primary efficacy outcome is change in the Montgomery-Åsberg Depression Rating Scale (MADRS, range 0-60) from post-treatment through 12-month follow-up, alongside tracking of stimulation-induced side effects.5
  • The system is branded the XCS (eXternally powered Cortical Stimulation) System, positioned as a middle rung between non-invasive TMS and invasive DBS, delivering TMS-grade stimulation at home via a wearable transmitter (“hat”).24
  • Preclinical and early human work — a collaboration with Rice University, Baylor College of Medicine and UTHealth Houston, with intraoperative studies at Baylor St. Luke’s Medical Center — showed the glass-sealed implant stimulated the brain through the dura and operated reliably in freely behaving pigs over roughly one month.63
  • Beyond depression, Motif has said it is exploring the DOT for bipolar disorder, OCD, Alzheimer’s disease and substance use disorder; the company is led by CEO Jacob Robinson.27

Footnotes

  1. https://news.google.com/rss/articles/CBMiswFBVV95cUxQZDhWRE5MWUx2OFB5c25sS0FpcllhaXhUTk94ZGVhNTNJcnJ2UDBUZjZVVFc1d2loZjZsYVZoV05zaWJER1JwYy1sdmNQOHRuTE5RTmVGSGliSmZQM3pic1BTbllEM3JiZ0ttOFRKeFktWWgwRDEydDFJY0ZFZ2F5a21jbVVTVEt4TnpucVBOMXJzMFpEbkloUXVRNGtGZ014cngwMGxsdUZaQUNBWEJ3NGV3UQ?oc=5 ↩ ↩2 ↩3

  2. https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression ↩ ↩2 ↩3 ↩4 ↩5

  3. https://doi.org/10.1101/2023.09.13.23295460 ↩ ↩2 ↩3

  4. https://insidebci.com/news/2026-04-27-motif-neurotech-dot-wins-fda-ide-for-first-clinical-trial-in-treatment-resistant-depression/ ↩ ↩2 ↩3

  5. https://clinicaltrials.gov/study/NCT07594483 ↩ ↩2 ↩3

  6. https://www.biospace.com/motif-neurotech-conducts-first-in-human-brain-stimulation-with-millimeter-sized-implantable-device-for-treatment-resistant-depression ↩

  7. https://www.statnews.com/2026/04/27/motif-neurotech-gets-fda-nod-brain-implant-depression/ ↩

Graph View